Shares of Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) traded up 0.7% during trading on Friday . The stock traded as high as $4.40 and last traded at $4.40. 250 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 1,170 shares. The stock had previously closed at $4.37.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. HC Wainwright upgraded shares of Idorsia from a “neutral” rating to a “buy” rating in a research note on Monday, September 15th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Idorsia in a research note on Friday, August 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.
Check Out Our Latest Stock Analysis on Idorsia
Idorsia Trading Up 0.7%
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases.
Recommended Stories
- Five stocks we like better than Idorsia
- The How And Why of Investing in Oil Stocks
- Amazon Earnings: 3 Catalysts That Could Drive Shares to $300
- Asset Allocation Strategies in Volatile Markets
- Why Chipotle Stock May Bounce After a Brutal Sell-Off
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why VGT May Be a Smarter Bet Than Chasing Individual Tech Stocks
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
